JOH. BERENBERG, GOSSLER & CO. KG Notification in accordance with Art. 5 (4) (b) and (5) of Regulation (EU) No 596/2014

Transparency directive : regulatory news

09/03/2018 18:48

DGAP-News: Joh. Berenberg, Gossler & Co. KG / Key word(s): Miscellaneous
Notification in accordance with Art. 5 (4) (b) and (5) of Regulation (EU) No 596/2014 (news with additional features)

09.03.2018 / 18:48
The issuer is solely responsible for the content of this announcement.


Notification in accordance with Article 5 (4) (b) and (5) of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ('Market Abuse Regulation') of 16 April 2014 and in accordance with Article 8 (f) and Article 6 (2) of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 on regulatory technical standards for the conditions applicable to stabilisation measures

Notification of exercise of Greenshoe-Option in accordance with Article 8 (f) DelReg (EU) 2016/1052

The option granted by Dermapharm Holding SE to the stabilisation manager to purchase up to 1,755,000 additional shares in Dermapharm Holding SE at the offer price to the extent shares were placed under a securities loan in connection with over-allotments (so called Greenshoe-Option) was exercised by Joh. Berenberg, Gossler & Co. KG in the amount of 1,155,000 shares on 9 March 2018.

Notification of Stabilisation Measures in accordance with Article 6 (2) DelReg (EU) 2016/1052

Joh. Berenberg, Gossler & Co. KG (Kommanditgesellschaft) (limited partnership), registered with the Commercial Register (Handelsregister) of the Local Court (Amtsgericht) of Hamburg under HRA 42659, its registered office in Hamburg and business address at Neuer Jungfernstieg 20, 20354 Hamburg, in its capacity as Stabilisation Manager in connection with the initial admission to trading of newly issued ordinary bearer shares with a nominal value of EUR 1.00 per share of Dermapharm Holding SE (ISIN: DE000A2GS5D8; WKN: A2GS5D; ticker symbol DMP) on the regulated market (Prime Standard) of the Frankfurt Stock Exchange, has carried out during the time period from 28 February 2018 until and including 7 March 2018 stabilisation measures as further specified attached.


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=PAAJCTUBAP
Document title: Details of stabilization measures Dermapharm AG


09.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


662301  09.03.2018 

fncls.ssp?fn=show_t_gif&application_id=662301&application_name=news&site_id=symex


Other stories

20/05/2019 01:01
21/05/2019 06:27
21/05/2019 02:39
21/05/2019 07:00
21/05/2019 00:35
20/05/2019 20:36
20/05/2019 16:07
21/05/2019 01:01
20/05/2019 20:45
20/05/2019 18:48
21/05/2019 06:42
21/05/2019 06:00
20/05/2019 23:06
20/05/2019 01:01
20/05/2019 20:31
21/05/2019 08:31
21/05/2019 01:01
21/05/2019 07:00
21/05/2019 06:58
21/05/2019 01:01
20/05/2019 16:45
20/05/2019 20:19
21/05/2019 01:01
20/05/2019 09:42
19/05/2019 21:25
20/05/2019 22:24
21/05/2019 04:46
20/05/2019 15:48
20/05/2019 23:14
20/05/2019 13:40
20/05/2019 18:06
21/05/2019 08:00
20/05/2019 12:47
20/05/2019 17:12
21/05/2019 00:30
20/05/2019 08:13
20/05/2019 13:58
20/05/2019 17:17